This year’s Congress offered results on a promising treatment for metastatic breast cancer, as well as an update on Verzenio’s benefits for early-stage disease and other breast cancer research.
CAR-T cell therapy harnesses the immune system to attack blood cancers. The US Food and Drug Administration (FDA) is investigating whether it can give rise to secondary cancers.